The reduced expression of FRZB (SFRP3) in BMSCs via epigenetic silencing and the consequent activation of the Wnt/β-catenin pathway in HSPCs may also contribute to the disease progression of MDS [14]. This evidence concerns the gene FRZB and myelodysplastic syndrome.